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chronically treated patients could be considered as a positive trend. The project was 
fully supported by grant No. 103107 from the Charles University Grant Agency.
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OBJECTIVES: Intravenous (iv) infusion of biologic agents is a highly effective thera-
peutic option in treating active Rheumatoid Arthritis (RA) patients. In Greece, it is 
mandatory that all infusions are administered in a hospital setting, therefore, they are 
strongly correlated with the system’s capacity in terms of resources. The objective of 
this study was to assess the capacity of the Greek National Health System (NHS) 
hospitals to meet current and projected demand for the iv treatment of RA patients. 
METHODS: Semi-qualitative interviews on the basis of a strictly structured question-
naire were conducted with the Heads of all NHS RA infusion sites, to record available 
resources (staff, equipment, facilities), service utilization and ability to meet current 
and projected demand. The questionnaire was externally reviewed and piloted to a 
small sample before administration. Data were analyzed using SPSSv15.0. RESULTS: 
From a total of 31 NHS infusion sites (rheumatology clinics, outpatient departments, 
pathology clinics, day clinics), 28 responded (Response Rate 90.3%). On average, 
41.6% of Greek NHS RA patients are treated with a biologic agent. 64.2% of respon-
dents stated that available resources are insufﬁcient to meet current demand. The most 
important constraints in selection order were: space (92.8%), staff (89.2%), equip-
ment (iv-pumps, beds and chairs—64.2%) and working hours (60.7%). A total of 
56% of respondents stated that they may decline treatment to patients due to capacity 
constraints. Overall, respondents estimated that the number of iv patients could be 
increased by 104% on average, were there no capacity constraints. CONCLUSIONS: 
An important proportion of the estimated 40.000 RA patients in Greece, for whom 
iv biologic treatment in the hospital setting is essential for disease control, may be 
declined treatment due to constraints in RA-speciﬁc resources. Rationalization and 
reallocation of NHS resources is required to ensure equity in access to effective treat-
ment for all RA patients.
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OBJECTIVES: Osteoporotic vertebral fractures (OVF) are an important health 
concern which remain underdiagnosed in 70% cases. According to recent data, 
approximately 450,000 and 700,000 symptomatic vertebral fractures are diagnosed 
each year in the EU and in the US, respectively. The aim of this study is to understand 
the perceptions of primary care physicians (PCP) with regards to diagnosis and man-
agement of OVF in their consultations. METHODS: Exploratory design using qualita-
tive methodology. 15 semi-structured interviews, recorded and later transcribed, with 
PCP between 2006–2007. Subsequently two investigators from the research team 
carried out the analysis and crosschecked results by identifying categories. RESULTS: 
Suspected diagnosis of OFV is based on anamnesis, physical examination and a simple 
X-ray. Physicians inform that this work is not executed systematically in daily con-
sultations and sometimes chronic back pain is not studied in depth. The differential 
diagnosis is perceived as a complex process, leading to confusion (back pain, osteo-
arthritis, rheumatoid arthritis and osteoporosis). PCP agree radiology is useful in 
detecting a vertebral fracture. PCP refer patients to other specialists when they ﬁnd 
difﬁculties reaching a diagnosis (history of fractures, repeated fractures, persistent 
pain, suspicion of secondary osteoporosis,etc) and also when they are not allowed to 
carry out a densitometry in their primary care health centre. Regarding this test, par-
ticipants described a lack of both consensus and shared guidelines in its use. Minimally 
invasive surgical techniques are not widely known about and their access is irregular 
even when medical treatments are ineffective. CONCLUSIONS: Some recommenda-
tions have recently been proposed for OVF management. This study has identiﬁed a 
mismatch between the proposed recommendations and the ordinary clinical practice. 
PCP´s diagnosis is inﬂuenced by their personal interest in the osteoporosis ﬁeld, the 
degree to which they rely on published evidence and the proximity of surgical teams 
involved in this area.
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Saggia MG, Santos EA, Borges LG, Aguiar R
Roche Brazil, Sao Paulo, SP, Brazil
Findings from Finckh et al., 2007 suggest that rituximab may be a better treatment 
to rheumatoid arthritis (RA) patients who made use of a previous anti-TNF agent. 
The results from Hyrich et al, 2007 point out that the reasons for RA patients stopping 
a second drug are related to the reasons for stopping the ﬁrst drug. OBJECTIVES: To 
picture the scenario of the usage of anti-TNFs as 2nd line therapy for RA patients in 
the public health care sector in Brazil. To calculate the economic impact of rituximab 
incorporation as 2nd line RA therapy. METHODS: A database analysis on the use of 
anti-TNFs as 2nd line therapy for RA patients was conducted for the total period 
(November 2006-january 2009) available at DATASUS (www.datasus.gov.br) the 
government public database. We were able to identify therapeutic pathways of 5018 
patients up to December 2007. About 2.5% (122 patients) performed a switch to a 
second anti-TNF agent. An increasing in the use of anti-TNFs as 2nd line therapy was 
also identiﬁed. Then the current economic impact of anti-TNF treatment switches was 
calculated. Later, we substituted the second-line anti-TNF agents used for rituximab 
and compared the results. Drug costs were obtained from ‘Banco de Preços em Saúde’ 
(http://portal.saude.gov.br/bps/), the government ofﬁcial source. RESULTS: The use 
of anti-TNFs as 2nd line therapy for RA patients in the public health care sector in 
Brazil is a reality with a growing trend in Brazil. The use of rituximab, as a replace-
ment of a second anti-TNF agent for RA patients, has the potential of offering savings 
of about R$2.5 million for the public health care sector. CONCLUSIONS: The use 
of rituximab, as a replacement for anti-TNFs agents as 2nd line therapy for RA patients, 
could increase the clinical beneﬁts for RA patients and bring savings of about R$ 2,5 
million for Brazilian public health care system.
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OBJECTIVES: The aim of this study was to evaluate retrospectively the average 
annual direct costs of treating patients affected by rheumatoid arthritis (RA) with and 
without concomitant pathologies. METHODS: Resource consumption and direct 
medical costs of patients with a diagnosis for RA were estimated using year 2007 data 
from the administrative database of Piemonte Region (4,401,266 inhabitants). Patients 
affected by RA were divided in two sub-groups: with Regional Health Service (RHS) 
concomitant exemptions due to other chronic pathologies (WE) and without concomi-
tant exemptions (WoE). Resource consumption measured was the following: reim-
bursed drugs, diagnostic procedures, hospitalizations (including day hospital). The 
analysis was performed from the RHS perspective. Unit costs considered were prices 
and RHS reimbursement tariffs. RESULTS: WoE Patients were 6616 while WE 
patients were 5056. Mean age in the WoE group was 58.54 while in the WE group 
was 66.50. Distribution by age class showed that patients younger than 46 years were 
about 19% of the WoE group and about 5.5% of WE patients; patients older than 
65 years were more frequent in the WE population (58% vs. 38%, respectively). 
Annual average cost of treatment per patient amounted to a2182.52 in WoE patients 
and to a3587.42 in WE patients. Drug cost amounted to 53% of total cost for WoE 
patients and to 44% in WE patients; hospitalization costs amounted to 24.9% of total 
cost for WoE patients and to 34% for WE patients; day hospital and diagnostic pro-
cedures amounted to around 7% and 15% respectively in both groups. CONCLU-
SIONS: The analysis of a large database showed that patients with RA are frequently 
affected by other important chronic pathologies and that patients affected by RA and 
WoE have an annual RHS cost 40% lower than patients affected by RA and WE.
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OBJECTIVES: There is a growing emphasis in understanding reimbursement decisions 
for Rheumatoid Arthritis (RA), which ultimately affect patient access to treatments. 
Despite a wide variety of treatment options there are still patients who do not achieve 
an adequate response. To analyse demand and supply side of RA treatment the effects 
of multiple factors on prescriptions decisions (as written by the doctors) and reim-
bursement (Reimb) such as logarithmized prescriptions (ln_Rx), relevant therapeutic 
classes (ATC), logarithmized prices (ln_Price) and sales (ln_Sales) and disease preva-
lence (Prev) will be determined. METHODS: According to the underlying dependent 
variables different model speciﬁcation has been used. To explore the multiple variables 
affecting RA prescription a mixed model has been implemented whereas to analyse 
the shares of RA reimbursement levels a logistic regression has been chosen. RESULTS: 
The analyses include 6 years period (2003–2008) of prescription data for the EU5 
covering all ATC classes prescribed for RA. We found signiﬁcant effects on reimburse-
ment for ln_Rx (0.1868,p  0.0001), ln_Price (0.0189,p  0.0001), and country 
(France  1.1934, Germany  0.2542, Italy  0.1914 and Spain  1.1066). On 
prescriptions the results are highly signiﬁcant for ln_Sales (0.1793,p  0.0001), Reimb 
(0.1718,p  0.0001), ln_Price (0.2576,p  0.0001), Prev (0.5012,p  0.0001), and 
77% of all ATC classes. CONCLUSIONS: The results show that reimbursement seems 
to be negatively inﬂuence by supply (e.g. high retail prices in Germany) and demand 
(prescriptions) effects. These results are in line with national cost containment endea-
vours of payors. However, different factors such as promotion of generic drug usage 
in UK or high pharmaceutical consumption per person as in France combined with 
low prices seem to have stronger positive effects on reimbursement then in Spain, 
Germany, or Italy. As expected sales and further reimbursement opportunities are 
positively inﬂuencing the prescription of RA drugs whereas increasing prices are 
reducing RA related prescriptions. Interestingly, we see signiﬁcant positive epidemio-
logical demand factors such as an increasing RA prevalence.
